Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.29, $0.02 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $153.76 million versus the consensus estimate of $137.74 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.